03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
14:24 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Ultragenyx's Crysvita meets in Phase III for pediatric XLH

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Crysvita burosumab-twza (KRN23, UX023) met the primary endpoint of improving rickets compared with conventional therapy in the Phase III PIXLES trial to treat...
18:09 , Jun 1, 2018 |  BC Week In Review  |  Financial News

JHL raises $106M in bond deal

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised $106 million on May 15 in convertible bonds led by new investor VMS Investment Group, according to JHL CFO Ellis Chu. Also participating were new investor Ruihua...
18:00 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease (COPD) after the drug missed the primary endpoint of reducing exacerbations in a...
19:07 , May 30, 2018 |  BC Extra  |  Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease after the drug missed the primary endpoint of reducing exacerbations in a second...
16:45 , May 30, 2018 |  BC Extra  |  Financial News

JHL raises $106M in bond deal

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised $106 million in convertible bonds led by new investor VMS Investment Group, according to JHL CFO Ellis Chu. Also participating were Ruihua Investment, existing investor Milestone Capital...
14:13 , May 18, 2018 |  BC Week In Review  |  Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from TERRANOVA,...
18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool compound...
13:35 , May 11, 2018 |  BC Extra  |  Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from TERRANOVA,...